Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
The present invention relates to a compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid. The invention also relates to a mutein derived from a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat α2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having binding specificity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein said mutein: (a) comprises amino acid replacements at least one of the sequence position corresponding to sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, and (b) binds human CTLA-4 with a K D of 50 nM or less. The invention also relates to a pharmaceutical composition comprising such a compound or mutein as well as to various pharmaceutical uses of such a compound or mutein, for example, for the prevention and/or treatment of cancer, an auto-immune disease or an infectious disease.
1. A mutein derived from human neutrophil gelatinase-associated lipocalin (hNGAL), said mutein having binding specificity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein said mutein:
(a) comprises the amino acid sequence of SEQ ID NO: 79 but for at least 12 amino acid replacements selected from the group consisting of A40R, A40Y, E44D, E44N, K46Q, K46R, D47H, D47Y, Q49M, K50Q, K50N, K50D, L70I, F71S, F71L, R72S, R72P, R72D, K73H, K73T, D77E, W79T, W79P, N96D, P101G, P101R, G102D, G102M, L103K, L103D, A125L, A125Q, V126A, S127E, S127N, S127G, Q128D, Q128H, N129D, R130A, R130T, Y132F, and Y132H; and
(b) binds human CTLA-4 with a K D of 50 nM or less.
2. The mutein of claim 1 , wherein said mutein: blocks the interaction between CTLA-4 and its physiological ligands CD80 (B7-1) and/or CD86 (B7-2).
3. The mutein of claim 1 , wherein the mutein binds human CTLA-4 with a K D of 25 nM or less.
4. The mutein of claim 1 , wherein the mutein binds murine CTLA-4 with a K D of 200 nM or less.
5. The mutein of claim 1 , wherein the specificity of binding expressed as the
ratio r=K D for the complex between mutein and human CTLA-4 /K D for the complex between mutein and murine CTLA-4
has a value of 20 or less, or of 1 or less, or of 0.5 or less.
6. The mutein of claim 1 , wherein at least one of said amino acid replacements is F71S.
7. The mutein of claim 1 , wherein at least one of said amino acid replacements is R72S.
8. The mutein of claim 1 , which has an amino acid sequence further differing from that corresponding to SEQ ID NO: 79 by additionally at least one of the amino acid replacements selected from the group consisting of 155V, N65D, Q88R, N114D, N116S, H118Y, and M120V.
9. The mutein of claim 1 , which has an amino acid sequence further differing from that corresponding to SEQ ID NO: 79 by additionally at least one of the amino acid replacements selected from the group consisting of S14C, N21C, E60C, V84C, Q88C, N116C, T141C, E143C, A145C, S146C, and S158C.
10. The mutein of claims 1 , wherein the mutein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 37, 47, 48, 49, 50, 51, 52, 53, 54, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, and 73.
11. The mutein of claim 1 , wherein the mutein is conjugated to a compound selected from the group consisting of an organic molecule, an enzyme label, a radioactive label, a fluorescent label, a chromogenic label, a luminescent label, a hapten, biotin, a metal complex, a metal, colloidal gold, a cystostatic agent, a toxin and a moiety that extends the serum half-life of the mutein.
12. The mutein of claim 1 , wherein the mutein is conjugated to a toxin selected from the group consisting of pertussis-toxin, diphtheria toxin, ricin, saporin, pseudomonas exotoxin, calicheamicin, a taxoid, a maytansinoid, a tubulysin auristatin E, monomethylauristatin E, auristatin PYE and auristatin PHE.
13. The mutein of claim 11 , wherein the moiety that extends the serum half-life of the mutein is selected from the group consisting of a polyalkylene glycol molecule, hydroxyethylstarch, a Fc part of an immunoglobulin, a CH3 domain of an immunoglobulin, a CH4 domain of human IgE, an albumin binding peptide, and an albumin binding protein.
14. The mutein of claim 1 , wherein the mutein is fused at its N-terminus and/or its C-terminus to a protein, a protein domain or a peptide.
15. The mutein of claim 14 , wherein the protein domain is a CH4 domain of human IgE, which extends the serum half-life of the mutein.
16. A nucleic acid molecule comprising a nucleotide sequence encoding a mutein of claim 1 .
17. A host cell containing a nucleic acid molecule of claim 16 .
18. A pharmaceutical composition comprising a mutein of claim 1 .